| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Immunoadsorption therapy is expected as a novel cure therapy for patients with dilated cardiomyopathy, so present study was performed in order to establish blood tests to efficiently treat those patients by this therapy. Autoantibodies against heart were measured in multiple ways using the blood of patients treated with “Advanced Medical Care B（MHLW）”. It was found that optimal treatment can be performed by measuring the autoantibody which could directly suppress heart function (Cardio-depressant autoantibody) before and after the immunoadsorption therapy against heart failure. Furthermore, it was also clarified that simple ELISA method can estimate the cardio-depressant autoantibody by simultaneously combining multiple autoantigens.
|
